Know Labs Beheer

Beheer criteriumcontroles 1/4

De CEO Know Labs is Ron Erickson, benoemd in Jan2023, heeft een ambtstermijn van 1.83 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 1.65M, bestaande uit 27.4% salaris en 72.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.38% van de aandelen van het bedrijf, ter waarde $ 343.75K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 1.8 jaar en 5.4 jaar.

Belangrijke informatie

Ron Erickson

Algemeen directeur

US$1.7m

Totale compensatie

Percentage CEO-salaris	27.4%
Dienstverband CEO	1.8yrs
Eigendom CEO	1.4%
Management gemiddelde ambtstermijn	1.8yrs
Gemiddelde ambtstermijn bestuur	5.4yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Ron Erickson's beloning veranderd ten opzichte van Know Labs's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	US$2m	US$453k	-US$17m
Jun 30 2024	n/a	n/a	-US$16m
Mar 31 2024	n/a	n/a	-US$21m
Dec 31 2023	n/a	n/a	-US$20m
Sep 30 2023	US$1m	US$371k	-US$20m
Jun 30 2023	n/a	n/a	-US$23m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	n/a	n/a	-US$19m
Sep 30 2022	US$2m	US$474k	-US$20m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$26m
Dec 31 2021	n/a	n/a	-US$25m
Sep 30 2021	US$2m	US$366k	-US$25m
Jun 30 2021	n/a	n/a	-US$22m
Mar 31 2021	n/a	n/a	-US$18m
Dec 31 2020	n/a	n/a	-US$16m
Sep 30 2020	US$827k	US$243k	-US$14m
Jun 30 2020	n/a	n/a	-US$12m
Mar 31 2020	n/a	n/a	-US$12m
Dec 31 2019	n/a	n/a	-US$10m
Sep 30 2019	US$291k	US$189k	-US$8m
Jun 30 2019	n/a	n/a	-US$5m
Mar 31 2019	n/a	n/a	-US$4m
Dec 31 2018	n/a	n/a	-US$3m
Sep 30 2018	US$201k	US$180k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 1.65M ) Ron } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 647.72K ).

Compensatie versus inkomsten: De vergoeding van Ron is gestegen terwijl het bedrijf verliesgevend is.

CEO

Ron Erickson (80 yo)

1.8yrs

Tenure

US$1,652,327

Compensatie

Mr. Ronald P. Erickson, J.D., also known as Ron, is the Founder of Know Labs, Inc. (formerly known as Visualant, Inc.) and has been its Chairman since February 2015 and Director since April 2003 and serves...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Ronald Erickson	Founder	1.8yrs	US$1.65m	1.38% $ 343.7k
Peter Conley	CFO & Senior VP of Intellectual Property	2.5yrs	US$804.13k	0.0092% $ 2.3k
John Cronin	Interim CTO & Independent Director	less than a year	US$79.54k	0.015% $ 3.7k
James Anderson	Chief Medical Officer and Chairman of Medical	6.2yrs	geen gegevens	geen gegevens
Leonardo Trautwein	Chief Commercial Officer	1.8yrs	geen gegevens	0.018% $ 4.6k
Jordyn Hujar	Chief of Staff	no data	geen gegevens	geen gegevens
Dominic Klyve	Chief Science Officer	less than a year	geen gegevens	geen gegevens

1.8yrs

Gemiddelde duur

69yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van KNW wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 1.8 jaar), wat duidt op een nieuw team.

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Ronald Erickson	Founder	21.6yrs	US$1.65m	1.38% $ 343.7k
John Cronin	Interim CTO & Independent Director	less than a year	US$79.54k	0.015% $ 3.7k
James Anderson	Chief Medical Officer and Chairman of Medical	6.2yrs	geen gegevens	geen gegevens
William Owens	Independent Director	6.5yrs	US$198.07k	0.88% $ 218.9k
Carl Sundberg	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Larry Ellingson	Member of Medical	5.6yrs	US$60.40k	0.015% $ 3.7k
Jon Pepper	Independent Director	18.6yrs	US$198.07k	0.48% $ 118.7k
Ichiro Takesako	Independent Director	11.9yrs	US$198.07k	0.14% $ 35.8k
Donna Ryan	Member of Medical	5.2yrs	geen gegevens	geen gegevens
Benjamin Smarr	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Jessica Zendler	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens
Mark Aloia	Member of Scientific Advisory Board	1.7yrs	geen gegevens	geen gegevens

5.4yrs

Gemiddelde duur

73yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van KNW wordt beschouwd als ervaren (gemiddelde ambtstermijn 5.4 jaar).

Know Labs Beheer

Beheer criteriumcontroles 1/4

Belangrijke informatie

Recente managementupdates

Know Labs, Inc Announces Executive Appointments

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. Announces Board Appointments

Recent updates

Know Labs, Inc Announces Executive Appointments

Know Labs Receives Non Compliance Letter from NYSE American Regarding Sections 1003(a)(ii) and 1003(a)(iii)

High number of new and inexperienced directors

Know Labs, Inc. Announces Board and Committee Changes

Know Labs, Inc. has completed a Composite Units Offering in the amount of $3.445 million.

Know Labs, Inc., Annual General Meeting, Sep 26, 2024

Know Labs, Inc. Publishes Clinical Results in Leading Diabetes Journal

Know Labs, Inc. Announces Further Interim Results from a Clinical Research Study

Know Labs, Inc. Announces the Appointment of Chris Somogyi as President, International

Know Labs, Inc. to Present Clinical Research At the 2024 American Association of Clinical Endocrinology Annual Meeting

Know Labs, Inc. has filed a Follow-on Equity Offering in the amount of $5 million.

Know Labs, Inc. Announces Interim Results from its Most Recent Clinical Research Study

Know Labs, Inc. Announces Board Appointments

Know Labs, Inc. Expands Board of Directors

Know Labs, Inc. has completed a Follow-on Equity Offering in the amount of $7 million.

Know Labs, Inc., Annual General Meeting, Sep 22, 2023

Know Labs, Inc. Demonstrates Improved Accuracy of Machine Learning Model for Non-Invasive Glucose Monitor

Know Labs Completes Build of Portable Generation 1 Prototype for Non-Invasive Glucose Monitoring

Know Labs, Inc. Furthers External Validation of Bio-RFID(TM) Technology with Study Published in Sensors Journal

Know Labs, Inc. Study Validates Technical Feasibility of Its Novel Sensor for Non-Invasive Glucose Monitoring

Know Labs, Inc. Announces Changes to Executive Leadership Team

Know Labs, Inc. Announces Management Changes

Know Labs Common Stock Deleted from OTC Equity

Know Labs, Inc. has completed an IPO in the amount of $7.2 million.

Know Labs, Inc., Annual General Meeting, Sep 15, 2022

Know Labs, Inc. Announces Executive Appointments

Know Labs, Inc. Announces Executive Appointments

Know Labs Outlines Preparations for Pre-Submission Meeting with FDA

Know Labs, Inc. announced delayed 10-Q filing

Know Labs, Inc. Receives IRB Approval to Begin Internal Clinical Trial of Non-Invasive Glucose Monitoring Technology Bio-RFID™

Know Labs, Inc. Announces Introduction of New KnowU™ Diagnostic Device

Know Labs Receives New Patent for Its Non-Invasive Diagnostic Technology Platform, Bringing Patents Issued and Pending to Nearly 60

Know Labs Announces Successful Results from Pre-Clinical Study Validating Bio-RFID™ Platform Technology

Know Labs, Inc. announced that it has received $14.279 million in funding

Texas Biomedical Research Institute Issues Preliminary Results for Know Labs, Inc.'s Particle Bulb's Ability to Inactivate the SARS-CoV-2 Virus

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd